急性肾损伤中预测肾脏替代治疗需求的生物标志物:系统评价与荟萃分析
该PRISMA系统评价与荟萃分析纳入63项研究、共15928例危重患者(每项研究中位数122.5例[31-1439]),评估生物标志物预测AKI患者接受RRT的性能。其中41项研究评估了13种生物标志物,NGAL证据量最大,尿NGAL合并AUC为0.720(95%CI 0.638-0.803),血NGAL为0.755(0.706-0.803)。血肌酐和胱抑素C合并AUC分别为0.764(0.732-0.796)和0.768(0.729-0.807);尿生物标志物中白介素-18、胱抑素C及金属蛋白酶组织抑制因子-2与胰岛素样生长因子结合蛋白-7乘积的合并AUC分别为0.668(0.606-0.729)、0.722(0.575-0.868)和0.857(0.789-0.925)。作者结论认为,尽管部分生物标志物显示出合理预测价值,但当前证据强度尚不足以常规用于指导RRT启动决策。
要点
- 尿NGAL合并AUC 0.720(95%CI 0.638-0.803),血NGAL 0.755(0.706-0.803),是证据量最大的生物标志物。
- 血肌酐合并AUC 0.764(0.732-0.796),血胱抑素C 0.768(0.729-0.807)。
- 尿生物标志物中,金属蛋白酶组织抑制因子-2与胰岛素样生长因子结合蛋白-7乘积合并AUC最高,为0.857(0.789-0.925)。
- 尿白介素-18合并AUC 0.668(0.606-0.729),尿胱抑素C 0.722(0.575-0.868)。
- 作者结论:现有证据强度尚不足以将生物标志物常规用于指导AKI患者RRT启动决策。
适用人群与场景
- 危重急性肾损伤患者,评估生物标志物预测接受肾脏替代治疗(RRT)的性能。
研究设计与关键结果
- PRISMA-guided系统评价与荟萃分析,纳入63项研究、共15928例危重患者(每项研究中位数122.5例[31-1439]),检索MEDLINE、Embase和CENTRAL数据库自建库至2017年9月。
- 41项研究评估了13种不同生物标志物;NGAL证据量最大,尿NGAL合并AUC 0.720(95%CI 0.638-0.803),血NGAL合并AUC 0.755(0.706-0.803)。
- 血肌酐合并AUC 0.764(0.732-0.796),血胱抑素C合并AUC 0.768(0.729-0.807)。
- 尿白介素-18合并AUC 0.668(0.606-0.729),尿胱抑素C合并AUC 0.722(0.575-0.868),金属蛋白酶组织抑制因子-2与胰岛素样生长因子结合蛋白-7乘积合并AUC 0.857(0.789-0.925)。
证据类型、等级与局限
- 证据类型:PRISMA-guided系统评价与荟萃分析。
- 作者结论:尽管若干生物标志物显示出应用前景和对危重AKI患者RRT使用的合理预测,但当前证据强度尚不足以常规用于指导RRT启动时机的决策。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,尽管部分生物标志物对危重AKI患者RRT使用有合理预测价值,但现有证据强度尚不足以常规用于指导RRT启动决策。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
PURPOSE: Acute kidney injury (AKI) frequently occurs in critically ill patients and often precipitates use of renal replacement therapy (RRT). However, the ideal circumstances for whether and when to start RRT remain unclear. We performed evidence synthesis of the available literature to evaluate the value of biomarkers to predict receipt of RRT for AKI.
METHODS: We conducted a PRISMA-guided systematic review and meta-analysis including all trials evaluating biomarker performance for prediction of RRT in AKI. A systematic search was applied in MEDLINE, Embase, and CENTRAL databases from inception to September 2017. All studies reporting an area under the curve (AUC) for a biomarker to predict initiation of RRT were included.
RESULTS: Sixty-three studies comprising 15,928 critically ill patients (median per study 122.5 [31-1439]) met eligibility. Forty-one studies evaluating 13 different biomarkers were included. Of these biomarkers, neutrophil gelatinase-associated lipocalin (NGAL) had the largest body of evidence. The pooled AUCs for urine and blood NGAL were 0.720 (95% CI 0.638-0.803) and 0.755 (0.706-0.803), respectively. Blood creatinine and cystatin C had pooled AUCs of 0.764 (0.732-0.796) and 0.768 (0.729-0.807), respectively. For urine biomarkers, interleukin-18, cystatin C, and the product of tissue inhibitor of metalloproteinase-2 and insulin growth factor binding protein-7 showed pooled AUCs of 0.668 (0.606-0.729), 0.722 (0.575-0.868), and 0.857 (0.789-0.925), respectively.
CONCLUSION: Though several biomarkers showed promise and reasonable prediction of RRT use for critically ill patients with AKI, the strength of evidence currently precludes their routine use to guide decision-making on when to initiate RRT.
参考来源
- Klein SJ, Brandtner AK, Lehner GF, et al. Biomarkers for prediction of renal replacement therapy in acute kidney injury: a systematic review and meta-analysis. Intensive Care Med. 2018. PMID: 29541790. doi:10.1007/s00134-018-5126-8
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。